(Q49616528)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29376520%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

title

Targeting minimal residual disease: a path to cure? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29376520%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

3

Scott R Manalis

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29376520%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

Marlise R Luskin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29376520%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Mark A Murakami

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29376520%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

David M Weinstock

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29376520%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

language of work or name

English

0 references

publication date

29 January 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29376520%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29376520%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29376520%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29376520%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

255-263

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29376520%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc.2017.125

13 March 2020

exact match

0 references

cites work

Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm--combined prospective analysis by the German AML Intergroup

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Acute lymphoblastic leukemia: a comprehensive review and 2017 update

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

The aggressive peripheral T-cell lymphomas: 2017.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Chemotherapy combinations with monoclonal antibodies in non-Hodgkin's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic O

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first-line chemotherapy for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Gastrointestinal stromal tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Minimal residual disease in acute myeloid leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Minimum lesion detectability as a measure of PET system performance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Preventing clonal evolutionary processes in cancer: Insights from mathematical models

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Adjuvant endocrine monotherapy for postmenopausal early breast cancer patients with hormone-receptor positive: a systemic review and network meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Minimal residual disease-directed therapy in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Flow cytometric monitoring of residual disease in acute leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Standardized flow cytometry for highly sensitive MRD measurements in B-cell acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

MRD in AML: does it already guide therapy decision-making?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Minimal residual disease in acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Has MRD monitoring superseded other prognostic factors in adult ALL?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML-15 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Relation of clinical response and minimal residual disease and their prognostic impact on outcome in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 From the Dutch Childhood Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

How I treat newly diagnosed chronic phase CML

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Moving treatment-free remission into mainstream clinical practice in CML.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Dynamics of chronic myeloid leukaemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Single-cell RNA-seq supports a developmental hierarchy in human oligodendroglioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Cancer stem cell definitions and terminology: the devil is in the details.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Interrupted vs. continued maintenance therapy in childhood acute leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Tracking the Evolution of Non-Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

A conduit to metastasis: circulating tumor cell biology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Microfluidic, marker-free isolation of circulating tumor cells from blood samples

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Does the mobilization of circulating tumour cells during cancer therapy cause metastasis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Liquid biopsies come of age: towards implementation of circulating tumour DNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Functional precision cancer medicine-moving beyond pure genomics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Mass Cytometry: Single Cells, Many Features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Single-cell analyses to tailor treatments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Seq-Well: portable, low-cost RNA sequencing of single cells at high throughput

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Droplet barcoding for single-cell transcriptomics applied to embryonic stem cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Highly Parallel Genome-wide Expression Profiling of Individual Cells Using Nanoliter Droplets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Scaling by shrinking: empowering single-cell 'omics' with microfluidic devices

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Precision medicine for cancer with next-generation functional diagnostics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Overview of a chemoresponse assay in ovarian cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Examining the utility of patient-derived xenograft mouse models.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Interrogating open issues in cancer precision medicine with patient-derived xenografts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Organoid models of human and mouse ductal pancreatic cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Dynamic BH3 profiling-poking cancer cells with a stick

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Blastic Plasmacytoid Dendritic Cell Neoplasm Is Dependent on BCL2 and Sensitive to Venetoclax.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

High-throughput measurement of single-cell growth rates using serial microfluidic mass sensor arrays.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Using buoyant mass to measure the growth of single cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Determining therapeutic susceptibility in multiple myeloma by single-cell mass accumulation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Live-cell mass profiling: an emerging approach in quantitative biophysics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Characterizing deformability and surface friction of cancer cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Hydrodynamic stretching of single cells for large population mechanical phenotyping

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Real-time deformability cytometry: on-the-fly cell mechanical phenotyping.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Analyzing cell mechanics in hematologic diseases with microfluidic biophysical flow cytometry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Bioluminescence Microscopy as a Method to Measure Single Cell Androgen Receptor Activity Heterogeneous Responses to Antiandrogens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Single-cell dissection of transcriptional heterogeneity in human colon tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Genetic interrogation of circulating multiple myeloma cells at single-cell resolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Location of residual viable tumor cells after neoadjuvant chemotherapy: A new concept with high prognostic performance in osteosarcoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Characterization of residual tumours at the primary site in patients with a near pathological complete response after neoadjuvant chemoradiotherapy for oesophageal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Preleukemia: one name, many meanings

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Evidence for field effect cancerization in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Molecular etiology of second primary tumors in contralateral tonsils of human papillomavirus-associated index tonsillar carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Evidence for field cancerization of the prostate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Clonality and field cancerization in intraductal papillary-mucinous tumors of the pancreas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Determining the origin of synchronous multifocal bladder cancer by exome sequencing.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Molecular determinants of tumor recurrence in the urinary bladder

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Molecular evidence supporting field effect in urothelial carcinogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Single cells from human primary colorectal tumors exhibit polyfunctional heterogeneity in secretions of ELR+ CXC chemokines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

Osimertinib benefit in EGFR-mutant NSCLC patients with T790M-mutation detected by circulating tumour DNA.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.125

inferred from DOI database lookup

7 January 2021

based on heuristic

The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29376520

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Hematopoietic malignancies demonstrate loss-of-function mutations of BAX

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29376520

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRC.2017.125

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29376520%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

13 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:29376520%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference